Cabaletta Bio, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 67.68 million compared to USD 52.98 million a year ago. Basic loss per share from continuing operations was USD 1.65 compared to USD 1.81 a year ago.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
10.8 USD | -1.95% | -18.84% | -52.38% |
Mar. 22 | HC Wainwright Adjusts Cabaletta Bio's Price Target to $30 From $25, Maintains Buy Rating | MT |
Mar. 21 | Cabaletta Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-52.38% | 531M | |
-2.54% | 103B | |
+1.85% | 95.28B | |
+1.46% | 22.15B | |
-15.71% | 21.02B | |
-8.58% | 18.15B | |
-38.74% | 16.73B | |
-12.86% | 16.05B | |
+5.53% | 13.68B | |
+34.63% | 12.17B |
- Stock Market
- Equities
- CABA Stock
- News Cabaletta Bio, Inc.
- Cabaletta Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023